Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Katharina Hopp

TitleAsst Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone3037244822
Email

    Collapse Biography 
    Collapse education and training
    Mayo Clinic, Rochester MNPhD12/2012Biochemistry & Molecular Biology
    Collapse awards and honors
    2018Dr. Vincent H. Gattone Research Award, PKD Foundation

    Collapse Overview 
    Collapse overview
    Dr. Hopp attempts to understand, through her research, the underlying pathomechanisms driving autosomal dominant polycystic kidney disease (ADPKD) progression. Specifically, she investigates genetic mechanisms driving phenotypic heterogeneity amongst patients by studying different murine models and by sequencing human samples. She also studies the renal cystic microenvironment to better understand the role of immune cells in ADPKD pathogenesis. Through this research, Dr. Hopp aims to identify novel pathways that can be translated into either pre-clinical or clinical trials geared to alleviate disease burden.

    Collapse Research 
    Collapse research activities and funding
    W81XWH-17-1-0107     (Katharina Hopp)Sep 1, 2017 - Mar 31, 2019
    DOD
    Application of the Sleeping Beauty transposon system to identify regulatory genes driving ADPKD cystogenesis and phenotypic heterogeneity
    Role: PI
    PKD Research Grant     (Katharina Hopp)Jul 1, 2018 - Jun 30, 2020
    PKD Foundation
    Understanding the role of CD8+ T-cells in halting renal cystogenesis
    Role: PI
    K01DK114164     (HOPP, KATHARINA)Aug 1, 2018 - Jul 31, 2023
    NIH
    Defining the functional role of T-cells in Autosomal Dominant Polycystic Kidney Disease pathology
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Bullock BL, Kimball AK, Poczobutt JM, Neuwelt AJ, Li HY, Johnson AM, Kwak JW, Kleczko EK, Kaspar RE, Wagner EK, Hopp K, Schenk EL, Weiser-Evans MC, Clambey ET, Nemenoff RA. Tumor-intrinsic response to IFN? shapes the tumor microenvironment and anti-PD-1 response in NSCLC. Life Sci Alliance. 2019 Jun; 2(3). PMID: 31133614.
      View in: PubMed
    2. Holditch SJ, Brown CN, Atwood DJ, Lombardi AM, Nguyen KN, Toll HW, Hopp K, Edelstein CL. A study of sirolimus and an mTOR kinase inhibitor (TORKi) in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease (ADPKD). Am J Physiol Renal Physiol. 2019 May 01. PMID: 31042058.
      View in: PubMed
    3. Montford JR, Bauer C, Dobrinskikh E, Hopp K, Levi M, Weiser-Evans M, Nemenoff R, Furgeson SB. Inhibition of 5-lipoxygenase decreases renal fibrosis and progression of chronic kidney disease. Am J Physiol Renal Physiol. 2019 Apr 01; 316(4):F732-F742. PMID: 30649890.
      View in: PubMed
    4. Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K. CD8+ T cells modulate autosomal dominant polycystic kidney disease progression. Kidney Int. 2018 12; 94(6):1127-1140. PMID: 30249452.
      View in: PubMed
    5. Boczek NJ, Hopp K, Benoit L, Kraft D, Cousin MA, Blackburn PR, Madsen CD, Oliver GR, Nair AA, Na J, Bianchi DW, Beek G, Harris PC, Pichurin P, Klee EW. Characterization of three ciliopathy pedigrees expands the phenotype associated with biallelic C2CD3 variants. Eur J Hum Genet. 2018 12; 26(12):1797-1809. PMID: 30097616.
      View in: PubMed
    6. Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, Audrézet MP, Hopp K, Porath B, Shi B, Baheti S, Senum SR, Arroyo J, Madsen CD, Férec C, Joly D, Jouret F, Fikri-Benbrahim O, Charasse C, Coulibaly JM, Yu AS, Khalili K, Pei Y, Somlo S, Le Meur Y, Torres VE, Harris PC. Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. Am J Hum Genet. 2018 05 03; 102(5):832-844. PMID: 29706351.
      View in: PubMed
    7. Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Bañales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrézet MP, Ferec C, Le Meur Y, Torres VE, Harris PC. Mutations in GANAB, Encoding the Glucosidase IIa Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet. 2016 06 02; 98(6):1193-1207. PMID: 27259053.
      View in: PubMed
    8. Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016 09; 27(9):2872-84. PMID: 26823553.
      View in: PubMed
    9. Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, Harris PC, Torres VE, Chini EN. Food Restriction Ameliorates the Development of Polycystic Kidney Disease. J Am Soc Nephrol. 2016 05; 27(5):1437-47. PMID: 26538633.
      View in: PubMed
    10. Ye H, Wang X, Sussman CR, Hopp K, Irazabal MV, Bakeberg JL, LaRiviere WB, Manganiello VC, Vorhees CV, Zhao H, Harris PC, van Deursen J, Ward CJ, Torres VE. Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies. J Am Soc Nephrol. 2016 05; 27(5):1312-20. PMID: 26374610.
      View in: PubMed
    11. Kline TL, Irazabal MV, Ebrahimi B, Hopp K, Udoji KN, Warner JD, Korfiatis P, Mishra PK, Macura SI, Venkatesh SK, Lerman LO, Harris PC, Torres VE, King BF, Erickson BJ. Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease. Magn Reson Med. 2016 Apr; 75(4):1466-73. PMID: 25974140.
      View in: PubMed
    12. Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC. Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. J Am Soc Nephrol. 2015 Oct; 26(10):2559-70. PMID: 25644115.
      View in: PubMed
    13. Gainullin VG, Hopp K, Ward CJ, Hommerding CJ, Harris PC. Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner. J Clin Invest. 2015 Feb; 125(2):607-20. PMID: 25574838.
      View in: PubMed
    14. Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE. Effects of hydration in rats and mice with polycystic kidney disease. Am J Physiol Renal Physiol. 2015 Feb 01; 308(3):F261-6. PMID: 25503729.
      View in: PubMed
    15. Hopp K. Improving HNF1ß mutation detection rates: can a weighted score of clinical and familial characteristics help? Kidney Int. 2014 Nov; 86(5):882-4. PMID: 25360493.
      View in: PubMed
    16. Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol. 2015 Jan; 26(1):39-47. PMID: 24994926.
      View in: PubMed
    17. Paul BM, Consugar MB, Ryan Lee M, Sundsbak JL, Heyer CM, Rossetti S, Kubly VJ, Hopp K, Torres VE, Coto E, Clementi M, Bogdanova N, de Almeida E, Bichet DG, Harris PC. Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families. Kidney Int. 2014 Feb; 85(2):383-92. PMID: 23760289.
      View in: PubMed
    18. Harris PC, Hopp K. The mutation, a key determinant of phenotype in ADPKD. J Am Soc Nephrol. 2013 May; 24(6):868-70. PMID: 23687354.
      View in: PubMed
    19. Hopp K, Ward CJ, Hommerding CJ, Nasr SH, Tuan HF, Gainullin VG, Rossetti S, Torres VE, Harris PC. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest. 2012 Nov; 122(11):4257-73. PMID: 23064367.
      View in: PubMed
    20. Rossetti S, Hopp K, Sikkink RA, Sundsbak JL, Lee YK, Kubly V, Eckloff BW, Ward CJ, Winearls CG, Torres VE, Harris PC. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol. 2012 May; 23(5):915-33. PMID: 22383692.
      View in: PubMed
    21. Hopp K, Heyer CM, Hommerding CJ, Henke SA, Sundsbak JL, Patel S, Patel P, Consugar MB, Czarnecki PG, Gliem TJ, Torres VE, Rossetti S, Harris PC. B9D1 is revealed as a novel Meckel syndrome (MKS) gene by targeted exon-enriched next-generation sequencing and deletion analysis. Hum Mol Genet. 2011 Jul 01; 20(13):2524-34. PMID: 21493627.
      View in: PubMed
    22. Vujic M, Heyer CM, Ars E, Hopp K, Markoff A, Orndal C, Rudenhed B, Nasr SH, Torres VE, Torra R, Bogdanova N, Harris PC. Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol. 2010 Jul; 21(7):1097-102. PMID: 20558538.
      View in: PubMed
    23. Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van't Hoff WG, Niaudet P, Niaudet WP, Torres VE, Harris PC. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int. 2009 Apr; 75(8):848-55. PMID: 19165178.
      View in: PubMed
    Hopp's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (127) concept(s)
    _
    Co-Authors Expand Description
    See all (12) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2019 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)